Platform
Company
Coagulation
Review status
Currently under review
Pending specialist review and validation.
This test measures the functional activity of factor VII, a clotting protein made in the liver that helps your blood form a stable clot after an injury. The assay uses a standardized dilution as part of the laboratory method to ensure accuracy and reduce interference.
Factor VII depends on vitamin K and works early in the clotting process with tissue factor. Measuring its activity helps assess how well the extrinsic pathway of coagulation is working and can guide evaluation when there are signs of a bleeding problem or an unexpected change in clotting tests.
Results help your care team understand why you might bruise or bleed more easily, or why a screening test like the prothrombin time is abnormal. Low factor VII activity can occur with an inherited deficiency, vitamin K deficiency, certain medications that affect vitamin K, or liver disease. High activity may be seen with hormonal therapy or during pregnancy, and has been linked in some studies to cardiovascular risk, but interpretation depends on the overall clinical picture.
Clinicians order this test to investigate unexplained bleeding, to characterize a prolonged clotting screen, to plan procedures in people with known or suspected factor VII deficiency, and to monitor or tailor replacement therapy during treatment for a rare bleeding disorder.
Your provider will interpret factor VII activity together with your history, medications, diet, and other lab tests. A result lower than expected suggests reduced factor function, which can be inherited or acquired. If acquired causes are suspected, your team may check vitamin K status, review liver health, and look for effects of medicines that alter clotting. Sometimes additional studies, such as mixing studies or specific inhibitor testing, are used to clarify the cause.
If activity is higher than expected, it is usually interpreted alongside other risk factors and is not used on its own to diagnose a clotting tendency. Depending on your situation, your provider may recommend repeating the test, adjusting medications, addressing nutrition, or discussing targeted therapy if a true deficiency is confirmed. Do not change any treatments without medical advice.
Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.
Low vitamin K intake, malabsorption, or recent use of broad‑spectrum antibiotics can reduce factor VII production and lower measured activity.
Vitamin K antagonists used for anticoagulation lower factor VII first, and some antibiotics or high‑dose salicylates may influence results. Always list all medicines and supplements.
Improper tube fill, wrong citrate ratio, delayed processing, or excessive chilling or heating can artifactually change activity. Ensure the blue‑top tube is filled and processed promptly.
Because factor VII is made in the liver, liver inflammation or injury can reduce its activity. Abnormal liver tests may help explain a low result.
Pregnancy and estrogen‑containing therapies can increase factor VII activity. Your provider may interpret results using clinical context related to hormones.
Some clot‑based assays are variably affected by newer blood thinners. Timing the blood draw relative to dosing or using drug‑insensitive methods may be needed.
Infusion of plasma or factor concentrates can transiently raise activity, potentially masking an underlying deficiency if blood is drawn soon after treatment.
References